Acetato de Caspofungin (Cancidas®) in the Treatment of Fungal Infection

CompletedOBSERVATIONAL
Enrollment

320

Participants

Timeline

Start Date

March 31, 2004

Study Completion Date

February 29, 2008

Conditions
CandidiasisAspergillosis
Interventions
DRUG

Caspofungin

The patients are treated with 70 mg IV of caspofungin on day 1, followed by 50 mg/day IV during the rest of treatment

Trial Locations (27)

Unknown

Hospital General de Alicante, Alicante

Hospital Germans Trias i Pujol, Badalona

Hospital Clínico y Provincial de Barcelona, Barcelona

Hospital de la Santa Creu i Sant Pau, Barcelona

Hospital vall d'Hebrón, Barcelona

Institut Català d'Oncología, L'Hospitalet de Llobregat

Xarxa assistencial de Manresa, Manresa

Hospital Universitario Marqués de Valdecilla, Santander

Hospital general de Castellón, Castelló

Hospital Puerta del Mar, Cadiz

Complejo Hospitalario Reina Sofía, Córdoba

Hospital Universitario Virgen de las Nieves, Granada

Hospital Juan Canalejo, A Coruña

Complejo Hospitalario Universitario de Santiago, Santiago de Compostela

. Hospital Clínico Universitario Virgen de la Victoria, Málaga

Hospital Carlos Haya, Málaga

Hospital Son Dureta, Palma de Mallorca

Hospital Son Llàtzer, Palma de Mallorca

Hospital Universitario Virgen del Rocío, Seville

Hospital Universitari de Tarragona Joan XXIII, Tarragona

Hospital Verge de la Cinta, Tortosa

Hospital Clínico de Valencia, Valencia

Hospital La Fe, Valencia

Hospital Universitario Dr. Peset, Valencia

Complejo Hospitalario Xeral-Cies, Vigo

Area Hospitalaria Juan Ramón Jimenez, Huelva

Hospital general de Jerez de la Frontera, Jerez de la Frontera

All Listed Sponsors
collaborator

GTEI

UNKNOWN

collaborator

SEMICYUC

UNKNOWN

lead

PETHEMA Foundation

OTHER

NCT00388167 - Acetato de Caspofungin (Cancidas®) in the Treatment of Fungal Infection | Biotech Hunter | Biotech Hunter